Spear Bio expands NAB-Sure™ Assays to Support Study of SARS-CoV-2 Variants
(WOBURN, MA) Dec 22, 2022 — Spear Bio is expanding its NAB-Sure™ Neutralizing Antibody Test Kit product line with current SARS-CoV-2 variants. This addresses the need of researchers and vaccine developers faced with emerging SARS-CoV-2 variants as they continue to study immune responses to COVID-19 and protection durability of vaccines.
Earlier this year Spear Bio introduced NAB-Sure™, a cell-free assay, which uses real-time PCR systems to quantify neutralizing antibodies (NAbs) from plasma, serum, or dried blood spot (DBS) samples. This assay can be used to monitor the humoral response in populations of interest post-vaccination or post-booster and show neutralizing antibody durability in longitudinal studies. The first product was focused on SARS-CoV-2 wild type, original strain.
Following growing customer interest, Spear Bio is now expanding NAB-Sure™ with an array of relevant SARS-CoV-2 variants: Omicron BA.4/5 is the first one, additional variants (e.g., BA.1, BQ.1, XBB) are to follow in the next few weeks.
“Whether for public health surveillance, clinical research, or vaccine development, researchers are continually studying patient serology. This is key to understanding the immune response to vaccines and infection.” said Jerome Clavel, CEO of Spear Bio. “We are working with our customers to identify key variants needed by researchers in their ongoing work.”
NAB-Sure™ – research use only – assay offers researchers a highly sensitive, accurate and precise cell-free alternative to neutralizing antibody testing. Key features include:
- PRNT level accuracy with qPCR
- High lab-to-lab consistency
- Easy to use workflow
- High throughput with automation compatibility
- 6-hours test time
- Quantitative and qualitative NAb measurements
About Spear Bio
Spear Bio (www.spear.bio), founded in 2021 by Harvard researchers at the Wyss Institute, is headquartered in Woburn, MA. The company is devoted to the next generation of ultrasensitive immunoassay technology and collaborates closely with academic researchers, clinicians, and industry to develop more ultrasensitive detection approaches in support of clinical research, non-invasive sample collection methods, and cutting-edge laboratory diagnostics.
Contact: Oliver Tassinari, Sr. Director of Business Development, firstname.lastname@example.org